Compumedics Limited (ASX:CMP) Chairman's Address To Shareholders
Melbourne, Oct 29, 2015 - (ABN Newswire) - Compumedics Limited (ASX:CMP) is a leading global, innovative developer and manufacturer of medical devices for:
- Diagnosing sleep disorders
- Monitoring neurological disorders including long-term epilepsy monitoring (LTEM)
- Highly sophisticated brain research
- Ultrasonic monitoring of blood flow through the brain (Transcranial Doppler [TCD])
* Compumedics is a technological leader in its chosen markets:
- #1 Australia sleep & neuro diagnostics device supplier
- #1Japan sleep diagnostics device supplier
- #1 China sleep diagnostic device supplier to China's premier facilities & #1 TCD device supplier
- #3 USA sleep diagnostic device supplier and emerging #3 supplier for neurological monitoring devices
* Compumedics has a rich intellectual property portfolio
* Compumedics e-Health platform is the next growth phase in the company's development
* Compumedics listed ASX Dec 21, 2000
Investor Overview
- FY 15 Highlights: $33.5m sales, revenue growth 9%, EBITDA $4.1m, NPAT $2.0m
- Core business: now highly profitable and continues to grow with the full benefits of the earnings initiatives undertaken in recent years still to flow through.
- New Product platform roll out to significantly expand our addressable market
- Growth in international sales with expansion plans in the US, Germany and China
- eHealth: Pushing ahead with the commercialization of our cloud based sleep diagnostics platform
- DWL expansion opportunity with newly granted breakthrough auto-scan TCD patent and Neuroscan foray into much larger brain analysis imaging market
- Spin offs/strategic decisions to unlock significant value for shareholders continue to be pursued
- FY16 guidance: Sales $36m-$38m, EBITDA $4.5m-$5.5m, NPAT $2.8m-$3.2m.
To view the Presentation, please visit: http://media.abnnewswire.net/media/en/docs/ASX-CMP-432740.pdf
About: Compumedics Limited
Compumedics Limited (ASX:CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.
Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades including Australia's exporter of the year and has been recognised as a Top 100 Innovator by both German and Australian Governments.
Help employers find you! Check out all the jobs and post your resume.
- Diagnosing sleep disorders
- Monitoring neurological disorders including long-term epilepsy monitoring (LTEM)
- Highly sophisticated brain research
- Ultrasonic monitoring of blood flow through the brain (Transcranial Doppler [TCD])
* Compumedics is a technological leader in its chosen markets:
- #1 Australia sleep & neuro diagnostics device supplier
- #1Japan sleep diagnostics device supplier
- #1 China sleep diagnostic device supplier to China's premier facilities & #1 TCD device supplier
- #3 USA sleep diagnostic device supplier and emerging #3 supplier for neurological monitoring devices
* Compumedics has a rich intellectual property portfolio
* Compumedics e-Health platform is the next growth phase in the company's development
* Compumedics listed ASX Dec 21, 2000
Investor Overview
- FY 15 Highlights: $33.5m sales, revenue growth 9%, EBITDA $4.1m, NPAT $2.0m
- Core business: now highly profitable and continues to grow with the full benefits of the earnings initiatives undertaken in recent years still to flow through.
- New Product platform roll out to significantly expand our addressable market
- Growth in international sales with expansion plans in the US, Germany and China
- eHealth: Pushing ahead with the commercialization of our cloud based sleep diagnostics platform
- DWL expansion opportunity with newly granted breakthrough auto-scan TCD patent and Neuroscan foray into much larger brain analysis imaging market
- Spin offs/strategic decisions to unlock significant value for shareholders continue to be pursued
- FY16 guidance: Sales $36m-$38m, EBITDA $4.5m-$5.5m, NPAT $2.8m-$3.2m.
To view the Presentation, please visit: http://media.abnnewswire.net/media/en/docs/ASX-CMP-432740.pdf
About: Compumedics Limited
Compumedics Limited (ASX:CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.
Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades including Australia's exporter of the year and has been recognised as a Top 100 Innovator by both German and Australian Governments.
Help employers find you! Check out all the jobs and post your resume.